bioihbjkbjnl/mcl2 huggingface dataset:
Comparison of Erector Spinae Plane Block and Combination of Deep and Superficial Serratus Anterior Plane Block
Condition: Pain, Postoperative; Thoracic Surgery, Video-Assisted; Erector Spinae Plane Block; Serratus Anterior Plane Block; Multimodal Analgesia
MeSH terms: Pain, Postoperative
Study type: Interventional

Summary: 
      Video-assisted thoracic surgery (VATS) has become a common procedure in thoracic surgery.
      Severe postoperative pain may be encountered in patients undergoing VATS. Analgesic methods
      such as thoracic paravertebral block (TPVB), intercostal block and erector spina plane block
      (ESPB) are widely used for VATS. Among these methods, ultrasound (US) guided TPVB is the most
      preferred method. In recent years, the frequency of application of plane blocks as a
      component of multimodal analgesia has been increased. ESPB and SAPB are some of them.
      Generally, comparisons are made between ESPB and TPVB in studies and the analgesic effect is
      evaluated.There are two techniques for SAPB application. In Deep SAPB (DSAPB) application,
      local anesthetic agent is given under the serratus anterior muscle. In the Superficial SAPB
      (SSAPB) application, the local anesthetic agent is given above the serratus anterior muscle.
      Since it is done by entering from the same point in two applications, it is possible to
      perform these two applications at the same time with a single needle entry. The mechanisms of
      regional analgesia techniques used after thoracic surgery operations are also different from
      each other. Therefore, it may be possible to obtain a more effective analgesic effect in
      patients by combining the mechanism of action of DSAPB and SSAPB , as in the multimodal
      analgesia method. This study seeks to evaluate the effect of ESPB and combined DSAPB-SSAPB
      pain after VATS.
    


Intervention name(s): Erector Spinae Plane Block; Deep and Superficial Serratus Anterior Plane Block
Intervention type(s): Procedure; Procedure
Intervention description(s): Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.; Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Condition: Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Clinically Isolated Syndrome
MeSH terms: Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Sclerosis
Study type: Observational

Summary: 
      This study will look at the blood and cerebrospinal fluid of consented participants who
      either have early stage multiple sclerosis (clinically isolated syndrome) or who have later
      stage (secondary progressive multiple sclerosis), or participants who do not have any
      neurological or autoimmune illness. Biomarkers and microRNA will be assessed for group
      differences.
    

Detailed description: 
      Multiple Sclerosis is a chronic autoimmune disorder of the central nervous system. While
      there are current immunomodulatory therapies that have been shown to be efficacious in the
      early stages of MS, these therapies are less potent in the later phases of MS. We can look at
      magnetic resonance imaging with gadolinium to measure active disease but it does not detect
      axonal degeneration. Therefore, there is a need to identify other biomarkers that may be used
      to diagnose MS and predict disease progression. Biomarkers found in the cerebrospinal fluid
      (CSF) are in closer proximity to the inflammatory lesion sites and are more sensitive.

      This pilot study seeks to characterize differences in microRNA profiles and cell products in
      the early and later stages of MS, with the hope that that microRNA profiles could then be
      correlated to clinical and CSF inflammation indexes. CSF will be obtained from 45
      participants.
    

Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        45 participants will be enrolled into a study to examine the microRNA and cell products
        profile in both cerebrospinal fluid (CSF) and blood. Study population will consist of a
        total of: 20 CIS patients defined as patients having a single attack (or the appearance of
        one or more symptoms characteristic of MS) high risk of developing MS, when no other
        diseases or causes are apparent.

        20 SPMS patients 5 normal, non-diseased controls
      
Biospecimen description: 
      Cerebrospinal fluid and blood may be stored for future immunological, cell product and
      microRNA testing related to the primary outcome of the this study.
    
Keywords: Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Clinically Isolated Syndrome
Full-spectrum Endoscopy in Colorectal Cancer Screening
Condition: Colorectal Cancer
MeSH terms: Colorectal Neoplasms
Study type: Interventional

Summary: 
      The purpose of this study is to compare the adenoma detection rates of full-spectrum
      endoscopy versus standard forward-viewing colonoscopy in colorectal cancer screening
      programme.
    

Detailed description: 
      Colorectal cancer is the third most common neoplasia and the second leading cause of cancer
      death in West countries. Colonoscopy is the gold standard for prevention of colorectal cancer
      disease. Screening for colorectal cancer with biennial faecal occult blood testing is a
      widely used strategy followed by colonoscopy for those with a positive test. Colonoscopy
      identifies polyps during the procedure as well as polyp removal in order to prevent
      progression to cancer. Although, interval cancer appears after a colonoscopy because of
      22-28% of polyp missed rates. Advanced Technology may improve adenoma detection rates so
      decrease interval cancer and reduce mortally. Full-spectrum endoscopy with 330º angle vision
      decrease adenoma miss rate in general population.

      The investigators conducted a randomized trial in patients from colorectal cancer screening
      programme (aged 50-69 years) after faecal immunological test positive. One arm the
      colonoscopy is performed with standard forward view colonoscopy (170º angle view) and the
      other arm is performed with full-spectrum endoscopy (EndoChoice) (330º angle view)
    

Intervention name(s): colonoscopy procedure
Intervention type(s): Procedure
Intervention description(s): endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Screening
Keywords: full-spectrum endoscopy; polyp detection rate; colorectal cancer; colorectal screening; adenoma detection rate; endoscopic innovations
Effectiveness of the Neural Mobilization on Upper Limb Functionality in Patients With Acquired Brain Injury
Condition: Hemiplegia and Hemiparesis; Acquired Brain Injury
MeSH terms: Brain Injuries; Hemiplegia; Paresis; Wounds and Injuries
Study type: Interventional

Summary: 
      The main objective:

      To determine changes in physiological and structural properties of upper limb muscles with
      spasticity in patients with acquired brain injury after applying neural mobilization
      improving their functional performance, their participation in society and quality of life.

      Hypothesis:

      Peripheral nerve mobilizations performed with neurodynamic techniques in upper limb in
      patients with acquired brain injury, generate changes at structural and physiological level,
      favoring the performance of daily life activities and improving the quality of life.
    

Detailed description: 
      Randomized clinical trial with blinding of the subject, the evaluator and the person
      analyzing the data.

      In the experimental group will be performed neural mobilitazion technique, while in the sham
      a technique to mimic neurodynamic.

      The assessment will be made by a single evaluator.
    

Intervention name(s): Neurodynamic; Mimic group
Intervention type(s): Other; Other
Intervention description(s): The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.; The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized Controlled Trial
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Acquired Brain Injury; Hemiplegia; Neural Mobilization; Upper limb
Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram
Condition: Healthy People
Study type: Interventional

Summary: 
      A prospective and observational clinical study of measuring the range of cardiac magnetic
      parameters in healthy people with the magnetocardiogram manufactured by Hangzhou Nuochi Life
      Science Co., LTD
    

Detailed description: 
      This study is a prospective and observational study on the collection of cardiac magnetic
      signals from healthy subjects by magnetocardiogram. It is expected that 412 subjects will be
      examined by magnetocardiography, and the range of parameters related to magnetocardiography
      in healthy subjects will be reported.
    

Intervention name(s): Magnetocardiogram
Intervention type(s): Diagnostic Test
Intervention description(s): Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      To evaluate and compare the relative bioavailability and therefore the bioequivalence of two
      different formulations of donepezil after a single oral dose administration under fasting
      conditions.
    

Detailed description: 
      Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover
      study under fasting conditions.
    

Intervention name(s): Donepezil
Intervention type(s): Drug
Intervention description(s): Donepezil Hydrochloride tablets,23 mg
Other intervention name(s): Aricept
Intervention MeSH terms: Donepezil
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 3

Summary: 
      Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This
      clinical study is designed to test the hypothesis that lurasidone is effective, tolerable,
      and safe as compared with quetiapine XR short term among acutely psychotic patients with
      chronic schizophrenia.
    


Intervention name(s): Lurasidone; Lurasidone; Quetiapine XR; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Lurasidone 80 mg tablets; Lurasidone 4 40 mg tablets; Quetiapine XR 600mg; Matching Placebo to Lurasidone or Quetiapine
Intervention MeSH terms: Quetiapine Fumarate; Lurasidone Hydrochloride
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Schizophrenia; SM-13496; Latuda; Lurasidone
Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
Condition: Alveolar Bone Preservation; Bone Graft
Study type: Interventional

Summary: 
      This is a prospective, outcomes assessor-blinded, randomized study to evaluate the efficacy
      and safety of "Inject BMP(Injectable Ceramics Bone Graft Substitute Containing rhBMP-2)" for
      socket preservation after extraction of a single-rooted tooth, compared to
      ExcelOS-inject(Injectable Ceramics Bone Graft Substitute).
    

Detailed description: 
      Inject BMP is Injectable Ceramics Bone Graft Substitute(ExcelOS-inject) containing rhBMP-2.
      Recombinant human Bone morphogenetic protein 2 (rhBMP-2) stimulates the production of bone.
    

Intervention name(s): Inject BMP; ExcelOS-inject
Intervention type(s): Device; Device
Intervention description(s): Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.; Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection
Condition: Seizures; Brain Diseases; Central Nervous System Diseases; Epilepsy; Nervous System Diseases; Neurologic Manifestations
MeSH terms: Seizures; Nervous System Diseases; Brain Diseases; Central Nervous System Diseases; Neurologic Manifestations
Study type: Interventional

Summary: 
      The ANSeR Clinical Investigation is a multi-centre, randomised, controlled, clinical
      investigation of a standalone decision support Algorithm for Neonatal Seizure Recognition,
      the ANSER Software system.
    

Detailed description: 
      This will be an open, two arm, parallel group, randomised, controlled investigation of the
      ANSeR Software System as a stand-alone neonatal seizure recognition decision support tool.
      Term neonates requiring EEG monitoring will be stratified by recruiting site and then
      randomised to receive either EEG monitoring with the ANSeR Software System or EEG monitoring
      without the ANSeR Software System.

      It is proposed that the rate of true detections (sensitivity) of investigation personnel
      using the ANSeR Software System in clinical practice will be at least 25% higher than that of
      investigation personnel not using the ANSeR Software System in routine clinical practice. In
      addition we expect the specificity of investigation personnel using the ANSeR Software System
      to be no worse than 10% less than that of investigation personnel not using the ANSeR
      Software System. This should result in more appropriate and timely use of antiepileptic drugs
      (AED).

      Randomisation Immediately following enrolment in the investigation, each participant will be
      randomly assigned to receive either EEG monitoring with the ANSeR Software System or without
      the ANSeR Software System. Randomisation will be stratified by recruiting site with a 1:1
      allocation ratio to each group. Block randomisation with varying block sizes will be used and
      the randomisation and allocation will be performed centrally using a web-based electronic
      system.

      Blinding As this is an investigation of a medical device (software), the investigation
      personnel will be aware of which group the participant is assigned to. The expert panel who
      are the diagnostic reference standard will be blinded to group allocation. The
      biostatistician will also be blinded to group allocation during the analysis of the data.
    

Intervention name(s): ANSeR Software System
Intervention type(s): Device
Intervention description(s): ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Other
Keywords: Neonatal Seizures; Decision Support Algorithm; EEG
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Condition: Gout
MeSH terms: Gout
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous
      doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects
      must wash out of any uric acid-lowering agents for one week before being dosed, and must
      refrain from using such agents throughout the study.
    


Intervention name(s): Puricase
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: elevated uric acid; Elevated serum uric acid level; Symptomatic gout
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension
Condition: Hypertension
MeSH terms: Hypertension
Study type: Interventional
Phase: Phase 4

Summary: 
      This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in
      blood pressure and heart rate in fed hypertensive subjects. Subjects are dosed with either
      Adalat or Coracten for first 2 weeks, followed by the other drug for 2 weeks, and then
      switched back to the original drug for one day. Blood samples, blood pressure, and heart rate
      are taken before and after each treatment period.
    


Intervention name(s): Adalat (Nifedipine, BAYA1040); Coracten
Intervention type(s): Drug; Drug
Intervention description(s): Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg; Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
Intervention MeSH terms: Nifedipine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Outcomes of Intra-Cytoplasmic Sperm Injection in Infertile Men With Non-tense Vaginal Hydrocele
Condition: Infertility, Male
MeSH terms: Infertility; Infertility, Male; Testicular Hydrocele
Study type: Observational

Summary: 
      Infertile men due to oligoasthenospermia with non-tense hydroceles are subjected to ICSI
    

Detailed description: 
      Sixty male infertile patients with Oligoasthenospermia were recruited from outpatient clinic
      of Urology Department, Tanta University. Patients were selected according to inclusion and
      exclusion criteria. The inclusion criteria were: (a) infertile couples due to male factor (b)
      Oligoasthenospermia (c) Normal hormonal profile (serum free and total testosterone,
      prolactin, Estrogen and LH), (d) presence or absence of non-tense vaginal hydrocel. The
      exclusion criteria were: (a) Presence of varicocele, (b) History of recent testicular trauma,
      (c) History of recent or old testicular inflammation, (d) Tense vaginal hydrocele and (e)
      presence of potential female pathologies.

      Sample size calculation: With H0 denoting higher success rates for ICSI in absence of
      non-tense hydrocele and confidence level of 95% and interval of 5 the sample size was 30. The
      program used was Epi info 0.7.

      Randomization and allocation: Enrolled patients were randomly allocated into 2 groups. The
      first group (n=30) who have oligoasthenospermia with non-tense vaginal hydrocele (Study
      group) and the second group (n=30) who have oligoasthenospermia with no hydrocele group
      (Control group). Randomization was done by computer-generated serial numbers where each
      number was enveloped. Each number denotes a certain allocation group. Allocation was by
      alternate method and envelope opening did not change allocation.

      Methods: Males were assessed by genital examination, ultrasound and scrotal Doppler. Female
      partners were given long agonist stimulation protocols, Ovum pickup fertilization by sperms
      and then embryo transfer on day 5. Demographic data of both couples, duration of infertility,
      seminal parameters (WHO-2010) and results of ICSI in these couples were recorded.
    

Intervention name(s): ICSI
Intervention type(s): Procedure
Intervention description(s): ICSI for both couples
Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        All infertile couples with male factor (oligoasthenospermia) due to non-tense hydrocele
      
Keywords: Infertility; male factor infertility; oligoasthenospermia; vaginal hydrocele
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is designed to compare the pharmacokinetics of three different formulations of
      Pf-04937319
    


Intervention name(s): Pf-04937319; Pf-04937319; Pf-04937319
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Formulation A) Pf-04937319 50 mg - administered as tablet; Formulation B) Pf-04937319 50 mg - administered as capsule; Formulation C) Pf-04937319 50 mg - administered as capsule
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: pharmacokinetics; relative bioavailability; formulation comparison